Understanding drug resistance in aggressive breast cancer
Revealing the hidden phosphoproteome of drug resistant triple negative breast cancer
This study is looking at triple negative breast cancer, which can be tough to treat, to find out why some cancer cells don't respond to usual therapies, and it hopes to discover new ways to help patients by understanding the proteins involved in this resistance.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Louisiana State Univ A&m Col Baton Rouge NIH-funded |
| Lab location | 1 site (Baton Rouge, United States) |
| Project ID | NIH-11143614 on NIH RePORTER |
What this research studies
This research focuses on triple negative breast cancer (TNBC), a highly aggressive form of breast cancer that often does not respond to standard treatments. The team is developing advanced techniques to analyze the phosphoproteome, which is crucial for understanding how cancer cells become resistant to therapies. By engineering specific protein domains and utilizing mass spectrometry, the researchers aim to uncover new insights into the signaling pathways that contribute to drug resistance in TNBC. This could lead to the identification of new therapeutic targets and strategies for overcoming resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who are experiencing resistance to standard chemotherapy treatments.
Not a fit: Patients with non-triple negative breast cancer or those who have not undergone chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with drug-resistant triple negative breast cancer.
How similar studies have performed: Previous research has shown promise in using phosphoproteomic approaches to understand cancer biology, indicating potential for success in this novel application.
Where this research is happening
Baton Rouge, United States
- Louisiana State Univ A&m Col Baton Rouge — Baton Rouge, United States (Active)
Researchers
- Principal investigator: Veggiani, Gianluca — Louisiana State Univ A&m Col Baton Rouge
- Study coordinator: Veggiani, Gianluca
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.